
https://www.science.org/content/blog-post/singlet-oxygen-pains
# Singlet Oxygen PAINS (March 2015)

## 1. SUMMARY

This short commentary article by Derek Lowe discusses Peter Kenny's analysis of "PAINS" (Pan-Assay Interference Compounds) in drug screening, specifically focusing on how some compound classes produce false positives through singlet oxygen scavenging mechanisms. The article highlights that the original PAINS research emerged from screening campaigns using AlphaScreen technology, which relies on singlet oxygen chemistry. Compounds containing double-bond-to-sulfur moieties (like rhodanines) can scavenge singlet oxygen, causing them to appear as false-positive hits in AlphaScreen assays. Lowe amplifies Kenny's concern while adding that these sulfur-containing compounds have multiple reactivity issues beyond just singlet oxygen scavenging, making them particularly problematic as screening hits that cannot be developed into viable drug candidates.

## 2. HISTORY

The PAINS concept, initially advanced by Baell and colleagues around 2010, has had lasting and measurable impact on drug discovery practices in the subsequent decade. Scientific publications increasingly incorporated PAINS filtering, with the original PAINS paper accumulating over 3,000 citations by 2023. Several follow-up studies validated the core premise, including independent analyses showing that PAINS compounds do indeed show disproportionate promiscuity across assay types.

On the software and informatics side, multiple cheminformatics tools incorporated PAINS filters (e.g., RDKit, ChemAxon, and commercial platforms), making PAINS screening standard practice in most pharmaceutical companies and academic screening centers. Major public databases (including PubChem and ChEMBL) added PAINS flags or alerts. This led to a measurable decrease in PAINS compounds appearing in high-throughput screening literature over time, as researchers adopted these filters.

However, some pushback and refinement occurred. Critiques emerged that the original PAINS classification was too binary and could flag some legitimate structures, leading to more sophisticated approaches incorporating additional assays to confirm genuine activity. The AlphaScreen technology itself remained widely used for specific applications like protein-protein interactions, with users increasingly aware of singlet-oxygen related artifacts.

Rhodanines and similar sulfur compounds largely disappeared from credible drug discovery programs after 2015, though they occasionally still appear in academic screening publications from less experienced groups.

## 3. PREDICTIONS

The article makes several implicit predictions:

• **That PAINS awareness would become widespread**: ✓ **Accurate**. As noted above, PAINS filters became standard practice throughout the pharmaceutical industry and academic drug discovery, with widespread tool adoption and literature awareness.
• **That AlphaScreen users would need greater awareness of singlet oxygen reactivity**: ✓ **Accurate**. Subsequent literature and assay protocols increasingly included warnings about singlet oxygen scavengers when using AlphaScreen or similar oxygen-dependent assay technologies.
• **That sulfur-containing compounds (rhodanines) would continue showing multiple problematic reactivities**: ✓ **Accurate**. Follow-up mechanistic studies confirmed rhodanines and related structures undergo various decomposition pathways, redox reactions, and multiple interference mechanisms, reinforcing their removal from legitimate screening libraries.

On the broader PAINS concept:
• **That PAINS understanding would improve screening hit quality**: ✓ **Accurate**. Retrospective analyses showed that PAINS filtering improved the success rate of hit-to-lead progression by reducing wasted effort on false positives.

## 4. INTEREST

Rating: **7/10**

This article captured an important methodological refinement in drug screening at the right time. While focused on a specific technical issue, it addressed a broader quality control problem that had significant practical impact on pharmaceutical R&D efficiency. The singlet oxygen mechanism insight was specific enough to provide actionable guidance while contributing to the larger PAINS narrative that reshaped screening practices industry-wide.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150318-singlet-oxygen-pains.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_